Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Cash from Financing Activities of -$4000.0 for Q4 2025, down 109.76% on a YoY basis from $41000.0 in Q4 2024, and down 101.67% sequentially from $240000.0 in Q1 2025.
Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Cash from Financing Activities data on file, last reported at -$4000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 109.76% year-over-year to -$4000.0; the trailing twelve-month figure through Dec 2025 stood at $236000.0 (down 26.48% YoY), and the FY2025 full-year result was $236000.0, down 26.48% from the prior year.
- Cash from Financing Activities retreated to -$4000.0 in Q4 2025, from $240000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $820000.0 in Q4 2021 to a low of -$4000.0 in Q4 2025.
- A 5-year average of $239705.9 and a median of $149000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 1390.0% in 2023 and sank 109.76% in 2025, its largest moves.
- Tracing RAPH's Cash from Financing Activities over 5 years: stood at $820000.0 in 2021, then plunged by 42.44% to $472000.0 in 2022, then sank by 95.97% to $19000.0 in 2023, then jumped by 115.79% to $41000.0 in 2024, then slumped by 109.76% to -$4000.0 in 2025.
- Business Quant data shows RAPH's Cash from Financing Activities at -$4000.0 in Q4 2025, $240000.0 in Q1 2025, and $41000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Dec 31, 2022 | 472,000.00 |
| Dec 31, 2022 | 472,000.00 |